Tocolytic therapy in preterm PROM

Clinical Obstetrics and Gynecology

Volumn 41, Issue 4, 1998, Pages 842-848

  Allen, Steven R ^a,b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MAGNESIUM SULFATE; UTERUS SPASMOLYTIC AGENT;

ANTIBIOTIC THERAPY; CHORIOAMNIONITIS; CORTICOSTEROID THERAPY; ENDOMETRITIS; GESTATIONAL AGE; LATENT PERIOD; NEWBORN MORBIDITY; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; REVIEW; TOCOLYSIS; TREATMENT CONTRAINDICATION;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; DELIVERY, OBSTETRIC; DRUG INTERACTIONS; FEMALE; FETAL MEMBRANES, PREMATURE RUPTURE; HUMANS; MORBIDITY; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY OUTCOME; STEROIDS; TOCOLYTIC AGENTS;

EID: 0032452975     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-199812000-00008     Document Type: Review

References (16)

1. Johnson JWC, Daikoku NH, Niebyl JR, et al. Premature rupture of the membranes and prolonged latency. Am J Obstet Gynecol. 1981;57:547-556.
2. Carlan SJ, O'Brien WF, Parsons MT, Lense JJ. Preterm premature rupture of membranes: A randomized study of home versus hospital management. Obstet Gynecol. 1993;81:61-64.
3. NIH Consensus Development Panel. Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA. 1995;273:413-418.
4. Mercer BM, Miodovnik M, Thurnau GR, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. JAMA. 1997;278: 989-995.
5. Cox SM, Leveno KJ. Intentional delivery versus expectant management with preterm ruptured membranes at 30-34 weeks' gestation. Obstet Gynecol. 1995;86:875-879.
6. Mercer BM, Crocker LG, Boe NM, Sibai BM. Induction versus expectant management in premature rupture of the membranes with mature amniotic fluid at 32 to 36 weeks: A randomized trial. Am J Obstet Gynecol. 1993;169:775-782.
7. Hallak M, Bottoms SF. Accelerated pulmonary maturation from preterm premature rupture of membranes: A myth. Am J Obstet Gynecol. 1993;169:1045-1049.
8. The Canadian Preterm Labor Investigators Group. Treatment of preterm labor with the beta-adrenergic agonist ritodrine. N Engl J Med. 1992;327:308-312.
9. Carroll SG, Sebire NJ, Nicolaides KH. Infection: Amniorrhexis, preterm delivery, neonatal sepsis. In: Nicolaides KH, ed. Preterm Prelabour Amniorrhexis - (Frontiers in Fetal Medicine Series). Pearl River, NY: The Parthenon Publishing Group, 1996:52-53.
10. Christensen KK, Ingemarsson I, Leideman T, et al. Effect of ritodrine on labor after premature rupture of the membranes. Obstet Gynecol. 1980;55:187-90.
11. Levy DL, Warsof SL. Oral ritodrine and preterm premature rupture of membranes. Obstet Gynecol. 1985;66:621-623.
12. Matsuda Y, Ikenoue T, Hokanishi H. Premature rupture of the membranes - aggressive versus conservative approach: Effect of tocolytic and antibiotic therapy. Gynecol Obstet Invest. 1993;36:102-107.
13. Garite TJ, Keegan KA, Freeman RK, Nageotte MP. A randomized trial of ritodrine tocolysis versus expectant management in patients with premature rupture of membranes at 25 to 30 weeks of gestation. Am J Obstet Gynecol. 1987;157:388-393.
14. Weiner CP, Renk K, Klugman M. The therapeutic efficacy and cost-effectiveness of aggressive tocolysis for premature labor associated with premature rupture of the membranes. Am J Obstet Gynecol. 1988; 159:216-222.
15. Decavalas G, Mastrogiannis D, Papadopoulos V, Tzingounis V. Short-term versus long-term prophylactic tocolysis in patients with preterm premature rupture of membranes. Eur J Obstet Gynecol Repro Bio. 1995;59:143-147.
16. Mercer BM, Lewis R. Preterm labor and preterm premature rupture of the membranes: diagnosis and management. Infect Dis Clin North Am. 1997;11:177-200.